Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · President and CEO | June 09, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date June 09, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 506,059 |
Ending reported balance
After 2023-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-09 · Grant · Acquired 70,769 · Balance 364,520 F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Row 2 · 2023-06-09 · Grant · Acquired 141,539 · Balance 506,059 F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-06-08 | Direct | 535,051 |
Reported balance
After 2023-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-09 · Grant · Acquired 141,539 · Balance 535,051 F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4: Represents the corrected number of securities owned due to a computational error in prior Form-4s |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
F4: Represents the corrected number of securities owned due to a computational error in prior Form-4s
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 141,539 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001367644-23-000119 · wk-form4_1686705615.xml · derivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 535,051 Underlying: Common Stock · 141,539 shares Expires 2030-06-08 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4 · balance_after: Represents the corrected number of securities owned due to a computational error in prior Form-4s Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 141,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000119 · wk-form4_1686705615.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,059 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| June 09, 2023 Filed Jun 14, 2023 01:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 70,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000119 · wk-form4_1686705615.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,520 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 38,462 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001367644-23-000071 · wf-form4_167814941740129.xml · derivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,182 Underlying: Common Stock · 38,462 shares Expires 2030-03-01 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 38,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000071 · wf-form4_167814941740129.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,751 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 00:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 19,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000071 · wf-form4_167814941740129.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,289 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. F2 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 19:42 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,226 | $12.38 | $39,937.88 |
DisclosureSEC source: 0001367644-23-000055 · wf-form4_167778610693108.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,298 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,591 | $13.71 | $21,812.61 |
DisclosureSEC source: 0001367644-23-000032 · wf-form4_167754730066296.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,524 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,428 | $14.30 | $20,420.40 |
DisclosureSEC source: 0001367644-23-000032 · wf-form4_167754730066296.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,115 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 4,944 | $13.25 | $65,508.00 |
DisclosureSEC source: 0001367644-23-000017 · wf-form4_167607935092887.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,543 F2 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 278 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000017 · wf-form4_167607935092887.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,487 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 16,961 shares of common stock, which is in excess of the 16,683 shares previously reported on February 25, 2020. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 135,330 | $41.38 Strike: $41.38 | $5,599,955.40 |
DisclosureSEC source: 0001367644-22-000044 · wf-form4_164626713300332.xml · derivative · entry 4 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,330 Underlying: Common Stock · 135,330 shares Expires 2029-02-28 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 55,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000044 · wf-form4_164626713300332.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,684 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 33,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000044 · wf-form4_164626713300332.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,102 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,715 | $39.64 | $67,982.60 |
DisclosureSEC source: 0001367644-22-000044 · wf-form4_164626713300332.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,969 F3 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,034 | $42.47 | $86,383.98 |
DisclosureSEC source: 0001367644-22-000031 · wf-form4_164582744695738.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,269 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,419 | $42.23 | $59,924.37 |
DisclosureSEC source: 0001367644-22-000031 · wf-form4_164582744695738.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,303 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 4,595 | $42.23 | $194,046.85 |
DisclosureSEC source: 0001367644-22-000022 · wf-form4_164574700044851.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,722 F2 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000022 · wf-form4_164574700044851.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,317 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 16,065 shares of common stock, which is in excess of the 11,801 shares previously reported on February 28, 2019. Read SEC document |
| May 08, 2021 Filed May 11, 2021 20:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 94 | $61.62 | $5,792.28 |
DisclosureSEC source: 0001367644-21-000077 · wf-form4_162076469265250.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,053 F1 · security: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 860 | $97.15 | $83,549.00 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,147 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,716 | $97.15 | $166,709.40 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,007 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 59,898 | $93.49 Strike: $93.49 | $5,599,864.02 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,898 Underlying: Common Stock · 59,898 shares Expires 2028-02-23 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,425 | $93.49 | $226,713.25 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,723 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 14,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,148 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 14,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000046 · wf-form4_161437780493924.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,173 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 423 | $123.45 | $52,219.35 |
DisclosureSEC source: 0001367644-21-000016 · wf-form4_161309658433305.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,198 F2 · security: Represents shares of common stock withheld to pay taxes due upon vesting of the PSUs. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000016 · wf-form4_161309658433305.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,621 F3 · security: Consists of PSUs previously granted on May 8, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year,as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 969 shares of common stock, which is in excess of the 646 shares previously reported on May 10, 2018. F3 · shares: Consists of PSUs previously granted on May 8, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year,as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 969 shares of common stock, which is in excess of the 646 shares previously reported on May 10, 2018. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,870 | $123.45 | $477,751.50 |
DisclosureSEC source: 0001367644-21-000016 · wf-form4_161309658433305.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,298 F2 · security: Represents shares of common stock withheld to pay taxes due upon vesting of the PSUs. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000016 · wf-form4_161309658433305.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,168 F1 · security: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 8,875 shares of common stock, which is in excess of the 5,917 shares previously reported on March 1, 2018. F1 · shares: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 8,875 shares of common stock, which is in excess of the 5,917 shares previously reported on March 1, 2018. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 13,000 | $120.03 Strike: $30.63 | $1,560,390.00 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,638 Underlying: Common Stock · 13,000 shares Expires 2024-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F5 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.19. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 32,397 | $120.03 Strike: $30.86 | $3,888,611.91 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · derivative · entry 5 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,397 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 13,000 | $120.03 | $1,560,390.00 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,210 F4 · security: Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F5 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.19. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 13,000 | $30.63 | $398,190.00 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 32,397 | $120.03 | $3,888,611.91 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,210 F1 · security: Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 32,397 | $30.86 | $999,771.42 |
DisclosureSEC source: 0001367644-21-000008 · wf-form4_161290942063298.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 21,900 | $110.03 Strike: $26.45 | $2,409,657.00 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,900 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.36. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 21,900 | $110.03 | $2,409,657.00 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,210 F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.36. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 21,900 | $26.45 | $579,255.00 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 2,232 | $110.00 Strike: $26.45 | $245,520.00 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · derivative · entry 5 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,900 Underlying: Common Stock · 2,232 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,232 | $110.00 | $245,520.00 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,210 F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 2,232 | $26.45 | $59,036.40 |
DisclosureSEC source: 0001367644-21-000006 · wf-form4_161135005224162.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 19,026 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001367644-21-000004 · wf-form4_161109171024831.xml · derivative · entry 3 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,026 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F1 · derivative.exercise_date: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 19,026 | $106.01 | $2,016,900.60 |
DisclosureSEC source: 0001367644-21-000004 · wf-form4_161109171024831.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,210 F1 · security: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.52 to $107.79. F3 · balance_after: The number of derivative securities beneficially owned was adjusted to account for a change in previously reported PSUs. 8,163 PSUs were previously reported, of which only 5,169 vested on February 11, 2020. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 19,026 | $25.62 | $487,446.12 |
DisclosureSEC source: 0001367644-21-000004 · wf-form4_161109171024831.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. F2 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · balance_after: The number of derivative securities beneficially owned was adjusted to account for a change in previously reported PSUs. 8,163 PSUs were previously reported, of which only 5,169 vested on February 11, 2020. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:27 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 95 | $79.25 | $7,528.75 |
DisclosureSEC source: 0001367644-20-000057 · wf-form4_158931524246734.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,203 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 778 | $58.42 | $45,450.76 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,424 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,126 | $59.91 | $67,458.66 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,298 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 558 | $59.91 | $33,429.78 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,202 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 66,731 | $61.44 Strike: $61.44 | $4,099,952.64 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,928 Underlying: Common Stock · 66,731 shares Expires 2027-02-24 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.